[ad_1]
Oak Brook, IL – The December edition of Discovery SLAS, “Drug Discovery Targeting COVID-19” is a special collection assembled by associate editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts towards the current global COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2.
In this special issue you will find seven articles published as open access articles. The issue includes four reviews covering the commonly used approach of reusing drugs to rapidly treat COVID-19, as well as targeting the virus using new vaccines and clinical drugs.
The original research papers focus on new proteins needed for virus replication. The article “High-Throughput Screening for Drugs that Inhibit Papain-Like Protease in SARS-CoV-2,” explores how a PLPro-targeted ultra-high-throughput screening platform has been used to investigate over 13,000 clinically applicable drugs. The article “Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3” verifies their effectiveness against the MAC domain of SARS2 Nsp3, a novel approach. In addition to these two articles, the December special issue contains two more original research articles.
Original research articles include:
- Method development and application of accelerated solution stability screening for drug discovery
- Comparative analysis of multiple immunoassays for cytokine profile in drug discovery
Other items include:
- Potential re-proposed therapies and new vaccines against COVID-19 and their clinical status
- A review of the preclinical and clinical efficacy of remdesivir, hydroxychloroquine and lopinavir-ritonavir treatments against COVID-19
- Based on the principles and insights of epidemiology, genome sequencing and COVID-19 pathogenesis: retrospective analysis of sinigrin and proloxin RX (fluphenazine) provides off-label drug candidates
- RNA-dependent RNA polymerase as a target for COVID-19 drug discovery
- Repurpose nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV2 receptor, as a therapeutic adjuvant to COVID-19
- Recommended guidelines for the development, qualification and implementation of complex in vitro models (CIVM) for drug discovery
- Drug Discovery Targeting COVID-19
###
Access in December Discovery SLAS the problem is available on https: /
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industrial and government life science researchers and developers and suppliers of laboratory automation technology. SLAS’s mission is to bring together researchers from academia, industry, and government to advance life science discovery and technology through education, knowledge exchange and global community building.
Discovery SLAS: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.195. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-Seven Therapeutics, Boston, MA (USA).
SLAS technology: Translating Life Sciences Innovation, 2019 Impact Factor 2.174. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases published on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
.
[ad_2]
Source link
